Aletti, Federico
Gambarotta, Nicolò
Penn, Alexander H.
Ferrario, Manuela
Schmid-Schönbein, Geert W.
Funding for this research was provided by:
Seventh Framework Programme (PIOF-GA-2012-328796, 602706)
National Institutes of Health (HL 67825, GM85072)
Article History
Received: 9 August 2015
Accepted: 7 December 2015
First Online: 19 December 2015
Compliance with ethical standards
:
: Geert W. Schmid-Schönbein owns stock in Inflammagen Inc., a company that develops new shock treatments.